These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8286931)

  • 21. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
    Morse MA
    Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential therapeutic application of antisense oligonucleotides in the treatment of ocular diseases.
    Danis RP; Henry SP; Ciulla TA
    Expert Opin Pharmacother; 2001 Feb; 2(2):277-91. PubMed ID: 11336586
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EuroTIDES 2005--Sixth Annual IBC Conference. Oligonucleotide, RNAi and peptides for the drug development and manufacturing industry.
    Corey DR
    IDrugs; 2006 Feb; 9(2):105-6. PubMed ID: 16523398
    [No Abstract]   [Full Text] [Related]  

  • 24. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
    Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
    Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antisense '97: a roundtable on the state of the industry.
    Nat Biotechnol; 1997 Jun; 15(6):519-24. PubMed ID: 9181572
    [No Abstract]   [Full Text] [Related]  

  • 26. Cell membranes as barriers for the use of antisense therapeutic agents.
    Jääskeläinen I; Urtti A
    Mini Rev Med Chem; 2002 Aug; 2(4):307-18. PubMed ID: 12370052
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Absorption, tissue distribution and in vivo stability in rats of a hybrid antisense oligonucleotide following oral administration.
    Agrawal S; Zhang X; Lu Z; Zhao H; Tamburin JM; Yan J; Cai H; Diasio RB; Habus I; Jiang Z
    Biochem Pharmacol; 1995 Aug; 50(4):571-6. PubMed ID: 7646565
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bioanalysis considerations on the pharmacokinetic evaluation of antisense therapeutics.
    Norris DA; Post N; Yu RZ; Greenlee S; Wang Y
    Bioanalysis; 2019 Nov; 11(21):1909-1912. PubMed ID: 31648523
    [No Abstract]   [Full Text] [Related]  

  • 29. ISIS-14803 (Isis Pharmaceuticals).
    Witherell GW
    Curr Opin Investig Drugs; 2001 Nov; 2(11):1523-9. PubMed ID: 11763152
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
    Orr RM
    Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Peptide-oligonucleotide hybrids in antisense therapy.
    Pierce TL; White AR; Tregear GW; Sexton PM
    Mini Rev Med Chem; 2005 Jan; 5(1):41-55. PubMed ID: 15638791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.
    Agrawal S
    Biochim Biophys Acta; 1999 Dec; 1489(1):53-68. PubMed ID: 10806997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antisense aims for a renaissance.
    Roush W
    Science; 1997 May; 276(5316):1192-3. PubMed ID: 9182327
    [No Abstract]   [Full Text] [Related]  

  • 34. Antisense oligonucleotides in cutaneous therapy.
    Wraight CJ; White PJ
    Pharmacol Ther; 2001 Apr; 90(1):89-104. PubMed ID: 11448727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery and development of respirable antisense therapeutics for asthma.
    Sandrasagra A; Leonard SA; Tang L; Teng K; Li Y; Ball HA; Mannion JC; Nyce JW
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):177-81. PubMed ID: 12162700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenges posed to the European pharmaceutical regulatory system by highly personalized medicines.
    Johnston JD; Feldschreiber P
    Br J Clin Pharmacol; 2014 Mar; 77(3):421-6. PubMed ID: 23738917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Skipping toward personalized molecular medicine.
    Hoffman EP
    N Engl J Med; 2007 Dec; 357(26):2719-22. PubMed ID: 18160693
    [No Abstract]   [Full Text] [Related]  

  • 38. Antisense strategy: biological utility and prospects in the treatment of hematological malignancies.
    Warzocha K; Wotowiec D
    Leuk Lymphoma; 1997 Jan; 24(3-4):267-81. PubMed ID: 9156656
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antisense oligonucleotides: efficient synthesis of 2'-O-methoxyethyl phosphorothioate oligonucleotides using 4,5-dicyanoimidazole. Are these oligonucleotides comparable to those synthesized using 1H-tetrazole as coupling activator?
    Wang Z; Siwkowski A; Lima WF; Olsen P; Ravikumar VT
    Bioorg Med Chem; 2006 Jul; 14(14):5049-60. PubMed ID: 16563772
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of progress in antisense therapeutics.
    Crooke ST
    Antisense Nucleic Acid Drug Dev; 1998 Apr; 8(2):115-22. PubMed ID: 9593049
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.